Clinical Trial

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will assess the pharmacokinetics (PK), safety, and tolerability of CAB ULA administered every 4 months (Q4M) following administration of CAB LA every 2 months (Q2M), in healthy adult volunteers.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-15; most recent amendment 2025-06-16.
Status change: Recruiting → Active, Not Recruiting 2025-06-16
Status change: Not Yet Recruiting → Recruiting 2025-02-17
Trial Details
NCT Number NCT06786520
Lead Sponsor ViiV Healthcare
Conditions HIV Infections
Enrollment 69 participants
Start Date 2025-01-17
Primary Completion 2027-03-09 (estimated)
Study Completion 2027-11-08 (estimated)
Updated on ClinicalTrials.gov 2025-06-19